TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Overall survival at 24 months
Endpoint domain: Mortality/survival
Primary endpoint: Local-regional control following salvage TL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glutathione peroxidase (GSHPx) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of thiobarbituric acid reactive products
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Necessity of online replanning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vowel and consonant identification score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of chronic anterior knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period of remission
Endpoint domain: Mortality/survival
Primary endpoint: intraplaque neovascularization reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percent change in weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in body cell mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Admission to the intensive care unit
Endpoint domain: Adverse events/effects
Primary endpoint: jaw-related health care expenditures
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Carers' reactions to symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Angiographic evidence of macular edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free survival at 3 years
Endpoint domain: Mortality/survival
Primary endpoint: Success rate of anesthetic injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum apoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of lumbar vertebral fractures
Endpoint domain: Adverse events/effects
Primary endpoint: BMD in lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and lymphatic system outcomes
Primary endpoint: Intervention-specific costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: agitation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to achieve full modified Aldrete score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Excessive postoperative bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: ICD Utilization Rate (UR)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Increase in Quit Line registrations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to sinus rhythm recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy rate during the first eight hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Central Endothelial Density (CED)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Angle Opening Distance (AOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0, infinity) for rizatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for rizatriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse experiences during coadministration
Endpoint domain: Adverse events/effects
Primary endpoint: percent of urine specimens that were negative for opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Defect depth reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Methamphetamine positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Craving scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depressive symptoms scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 7-day point prevalence abstinence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Evacuation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Induction-to-evacuation intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of hoarseness
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Cmax of zolmitriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean AUC of zolmitriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean t1/2 of zolmitriptan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reduction in seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: 50% responder rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: intention to engage in smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: smoking behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: local-regional failure rates
Endpoint domain: Mortality/survival
Primary endpoint: peak oxygen uptake indexed to fat‐free mass (VO(2peak)‐FFM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain assessment scoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Moderate to severe arthralgia/arthritis
Endpoint domain: Adverse events/effects
Primary endpoint: Trough plasma levels within target range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of natural pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: ECG ST segment shift
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AAR estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infarct size estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myocardial salvage estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMDQ score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Sick leave days due to LBP
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: number of spinal puncture failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Students reporting smoking-related messages
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Relative risk of students reporting ad promoted cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative risk for vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in initial insomnia
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: probing attachment level (PAL) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic bone level (RBL) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: residual probing pocket depth (PPD12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biopsy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intra‐epithelial lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti‐tissue transglutaminase IgA antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: nonfatal stroke or death
Endpoint domain: Mortality/survival
Primary endpoint: Safety of MSC infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Cutoff points for erythrocyte dysmorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average umbilical artery RI and PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Average uterine artery RI and PI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Estimated probabilities of bilateral uterine artery diastolic notching
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Frequency of sternal dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: β-cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevalence of atopic dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: CCOS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Involuntary loss of urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of AA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Median time to Tanner staging ≥ B4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of girls with Tanner staging ≥ B4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median sufentanil requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients requiring nefopam within 24 h of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median pain scores at post‐anaesthetic care unit admission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presyncope occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social impairment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Participation in competitive employment or school
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Cumulative number of weeks of schooling and/or employment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: safety and effectiveness of intensive BP lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean intensity of masseter muscle contractions during SB episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mean change in hot flush scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prescription of osteoporosis pharmacotherapy or hip protectors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: D-Roms levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of detectable HCV RNA from serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of CTI-TS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: post-operative ischemic brain injury
Endpoint domain: Mortality/survival
Primary endpoint: Total effective rates in adhesion stage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melle score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lag time to symptom report
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acid perfusion sensitivity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final HRSD score <= 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma homocysteine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum nicotine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: sensory ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sum strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal voluntary contract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Implementation scores of the intervention functions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of vaginal birth of healthy singletons at term
Endpoint domain: Mortality/survival
Primary endpoint: antibiotic prescription reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: antibiotic exposure reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: in-segment binary restenosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Executive function impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective rate of thrombolysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Rates of continuous treatment retention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rates of cross-sectional treatment engagement
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quality of Life (WORC score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Failure rate of rotator cuff repair
Endpoint domain: Adverse events/effects
Primary endpoint: Performance on clinical vignettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant HBV DNA at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: infant HBsAg positivity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maternal ALT elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Bias of pulse oximetry haemoglobin concentration measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Primary hemostasis with successful initial control of bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rebleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: 5-year liver-specific cumulative recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Mucosal IgG responses against HIV-antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine concentrations in genital secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plaque Index (PAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow in mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative visualization of the surgical field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ease of bowel handling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: overall ease of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Accelerated gastric emptying
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Increased glucose absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival rates of glass fibre and cast metal posts
Endpoint domain: Mortality/survival
Primary endpoint: Prandial glucagon AUC(0‐2 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Arterial oxygen tension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Initial manometric diagnosis achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis confirmation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall procedure tolerance
Endpoint domain: Adverse events/effects
Primary endpoint: Retention rates of enrolled families
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Avoidance of indicated Child Protective reports
Endpoint domain: Adverse events/effects
Primary endpoint: High rates of preventive care for enrolled children
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood loss between 500 ml and 1000 ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: number of instrumental vaginal births
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Manifest Refraction Spherical Equivalent (MRSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropathy grading score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area under the plasma concentration‐time curve (AUC0‐inf obv)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half‐life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD responses in brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PIPP scores at 90 seconds post lance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asymmetry Index (ASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Left Atrial Volume (LAV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atrial Fibrillation (AF) recurrence
Endpoint domain: Mortality/survival
Primary endpoint: DXA lean mass increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum level of chromium increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospitalizations or emergency department visits attributable to rotavirus gastroenteritis
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: vanishing rate and time needed of main symptoms and signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms score of SRP group
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Impacts scores of treatment groups
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Normalization of prolactin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Resolution of galactorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalization of sexual function
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pain relief time during first treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate after 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in QoL on the domain of Physical Health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients with scheduled weight monitoring
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAAS (Observer's Assessment of Alertness/Sedation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic necroinflammatory activity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of fibrosis reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained normalization of alanine aminotransferase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lysophosphatidylcholine (LPC 20:5) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phosphatidylethanolamine (PE 16:0/22:3) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sphingomyelin (SM d18:1/22:0) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased GM volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decreased FA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increased MD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 5% decline in VC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes